Immunohistochemistry or IHC
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
International Immunopharmacology 2020 April 24 [Link] Zhang F, Gong W Abstract OBJECTIVE:Programmed death ligand 1 (PD-L1) has been reported to be connected to prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no consensus based on data from previous studies. Accordingly, this quantitative meta-analysis investigated prognostic and clinicopathological utility of PD-L1 in patients…
Read MoreDefense and protection mechanisms in lung exposed to asbestiform fiber: the role of macrophage migration inhibitory factor and heme oxygenase-1.
European Journal of Histochemistry 2020 April 16 [Link] Loreto C, Caltabiano R, Graziano ACE, Castorina S, Lombardo C, Filetti V, Vitale E, Rapisarda G, Cardile V, Ledda C, Rapisarda V. Abstract Fluoro-edenite (FE), an asbestiform fiber, is responsible for many respiratory pathologies: chronic obstructive diseases, pleural plaques, fibrosis, and malignant mesothelioma. Macrophage migration inhibitory factor…
Read MoreComprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.
Journal of Thoracic Oncology 2020 March 9 [Link] Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R,…
Read MorePhotodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.
Cancers 2020 February 27 [Link] Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O Abstract The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that…
Read MoreA phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM)…
Read MoreAn in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.
Current Molecular Science 2020 February 20 [Link] Loreto C, Lombardo C, Caltabiano R, Ledda C, Hagnas M, Filetti V, Rapisarda V Abstract AIMS: The aim of this study was to investigate MacroH2A.1 immunoexpression in tissues of sheep exposed to FE. BACKGROUND: The correlation between asbestiform fibers, lung cancer, pleural mesothelioma and other lung diseases is…
Read MoreDifferential diagnosis of malignant pleural mesothelioma on cytology: a gene expression panel versus BAP1 and p16 tests.
Journal of Molecular Diagnostics 2020 February 6 [Link] Bruno R, Alì G, Poma AM, Proietti A, Libener R, Mariani N, Niccoli C, Chella A, Ribechini A, Grosso F, Fontanini G Abstract Pleural effusions are among the first clinical manifestations of malignant pleural mesothelioma (MPM) and often constitute the only available material for diagnosis. Although an…
Read MoreWell-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.
The American Journal of Case Reports 2020 January 13 [Link] Erem AS, Allamaneni SS, Braverman TS Abstract BACKGROUND Omental calcifications of the peritoneum are typically small and asymptomatic. However, larger psammomatous bodies that cause symptoms such as abdominal pain and bloating are often associated with tumors such as primary serous papillary carcinoma, mesothelioma, or metastatic…
Read MoreA gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations.
Oncology Letters 2020 January [Link] Alì G, Bruno R, Poma AM, Proietti A, Ricci S, Chella A, Melfi F, Ambrogi MC, Lucchi M, Fontanini G Abstract The demonstration of tissue invasion by histology is an essential criterion for the differential diagnosis of benign and malignant mesothelial proliferations. When tissue invasion cannot be identified, the use…
Read MoreMalignant Diffuse Mesothelioma in Women: A Study of 354 Cases.
The American Journal of Surgical Pathology 2019 December 23 [Link] Pavlisko EN, Liu B, Green C, Sporn TA, Roggli VL Abstract We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% pleural MM and 22% peritoneal MM. The…
Read More